Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503632 · ClinicalTrials.gov registry record · Phase 3
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
A Phase 3 study of Acute Lymphoblastic Leukemia, sponsored by Children's Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 570
- Enrollment target
- 20
- Study locations
NCT01503632 is a Phase 3 study of Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 570 participants, above the 378-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01503632, a Phase 3 study of Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 570 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia that has had a decrease in or disappearance of signs and symptoms of cancer (remission). Assessing ways to help patients who have acute lymphoblastic leukemia to take their medications as prescribed may help them in taking their medications more consistently and may improve treatment outcomes.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- BEHAVIORAL Behavioral Intervention
- DRUG Mercaptopurine
- BEHAVIORAL Compliance Monitoring
Study Locations (20)
Florida
- Lee Memorial Health System - Fort Myers
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- University of Florida Health Science Center - Gainesville - Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital - Hollywood
- Nemours Children's Clinic-Jacksonville - Jacksonville
- Nemours Children's Clinic - Orlando - Orlando
- Nemours Children's Hospital - Orlando
- Nemours Children's Clinic - Pensacola - Pensacola
California
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Mattel Children's Hospital UCLA - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
Connecticut
- Connecticut Children's Medical Center - Hartford
Delaware
- Alfred I duPont Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 570 participants |
| Start Date | 2012-02-21 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01503632
The ClinicalTrials.gov registry entry for NCT01503632 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 570 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 378-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (51% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01503632 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01503632 about?
NCT01503632 is a clinical study titled "Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission". This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia that has had a decrease in or disappearance of signs and symptoms of cancer (remission). Assessing ways to help patients wh...
What is the current status of trial NCT01503632?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 570 participants. The study started on 2012-02-21. Estimated completion is 2029-12-31.
What conditions does trial NCT01503632 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT01503632?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Behavioral Intervention (BEHAVIORAL), Mercaptopurine (DRUG), Compliance Monitoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT01503632?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01503632 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
ACTIVE NOT RECRUITING · Phase 3
-
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.